Fossel E. Improvement of temperature and flow in feet of subjects with diabetes with use of a transdermal preparation of L-arginine: a pilot study.

How To Use ED Gels Properly?

This stimulates the nerve endings on the head of the penis, which then leads to vasodilation and erection. It was approved by the Food and Drug Administration in June 2023 and is intended for men aged 22 years and older experiencing ED. The topical therapy has been shown to be safe and effective in two phase 3 clinical trials. Results from these studies showed over 60% of participants with mild, moderate or severe ED experienced a clinically meaningful improvement in erections with Eroxon. Seventy-one percent of participants were able to have penetrative sex within 15 minutes of application.

Register for resources and more

The gel was also found to be safe and well tolerated. Eroxon is supplied in a single-dose tube. The gel is compatible with latex and polyisoprene condoms, as well as lubricants. It has not been tested with contraceptive foams and gels. Individuals interested in pre-ordering Eroxon may do so through Amazon. Erectile dysfunction is the inability to achieve and maintain an erection.

Product Dosage Quantity + Bonus Price
Kamagra Gold50 mg60 + 4 Pills171.14€ 162.99€
Kamagra Oral Jelly100mg63 + 7 Sachets224.18€ 213.50€
Cialis Professional20mg30 Pills104.57€ 99.59€
Kamagra100mg180 + 6 Pills436.79€ 415.99€
Kamagra Oral Jelly100mg110 + 9 Sachets334.87€ 318.92€
Priligy Generic Dapoxetine60mg90 + 10 Pills265.64€ 252.99€
Levitra Generic20mg60 + 6 Pills131.11€ 124.87€
Viagra Generic150mg30 + 2 Pills72.32€ 68.88€
Kamagra Soft Tabs100mg12 Pills57.55€ 54.81€
Kamagra Gold100 mg180 + 6 Pills436.79€ 415.99€
Cialis Super Active20mg90 + 10 Pills314.14€ 299.18€
Super Kamagra160 mg12 Pills101.10€ 96.29€
Cialis Generic2.5mg120 + 6 Pills128.93€ 122.79€

It’s a condition that not many men feel comfortable talking about, but they should.

Sign up & save on Eroxon®

If you have further questions, feel free to reach out to Fagron Academy Technical Support Services! Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the United States. Drop-out reasons and complications in self-injection triple vasoactive drug mixture in sexual erectile dysfunction. Cuzin B. Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience.

Eroxon® is appropriate for a wide range of patients

Goldstein I, Payton T, Schechter P. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Ming Wen M El-Kamel A, Khalil S. Systemic enhancement of papaverine pink pills for woman transdermal gel for erectile dysfunction. Kim E, el-Rashidy R, McVary K. Erectile dysfunction isn’t only common, but it can also usually be treated. Treatments for erectile dysfunction are effective and evolving. Traditional oral medications can help, and drugs that you apply directly to the skin are being developed. Currently, there isn’t a gel or other topical drug approved by the U.

Advantages of Choosing Eroxon Gel

One placebo-controlled study compared sildenafil 1% gel to sildenafil 100mg tablets. The topical gel group applied 0.5g of sildenafil 1% gel to the glans of the penis approximately 5 minutes before sexual activity and the tablet group took a 100mg tablet 1 hour before sexual activity. In the gel group, 25% of patients achieved complete or moderate erections compared to 75% of the tablet group. Though oral tablets demonstrated increased likelihood of complete or moderate erection, both groups did see benefit and onset of erection in the patients who applied sildenafil gel was 7.4 ±3.6 minutes, but was 37.8 ± 14.9 minutes in the group who used oral tablets.7 Though there aren’t many other studies on sildenafil cream topical for erectile dysfunction, other studies for conditions such as Raynaud’s have demonstrated benefit and increased blood flow as a result of local administration of sildenafil 5% cream, further suggesting that sildenafil may be absorbed from topical administration.8 Though currently information regarding other in vivo studies on other PDE5 inhibitors topically for erectile dysfunction are not available, some studies have found benefit for tadalafil used topically for Raynaud’s, suggesting transdermal penetration and potential local efficacy.9 Future studies are needed to confirm the potential of tadalafil as a topical treatment for erectile dysfunction. Other active ingredients used transdermally to increase blood flow are sometimes also considered for combination topical ED mediations.

Avoid dubious or counterfeit products

Arginine, sometimes used at 3-6% in female sexual dysfunction creams, was found in a study of diabetic patients to improve blood flow. These patients applied transdermal arginine 12.5% cream to the feet and noted improved blood flow with a doppler flow meter and with an infrared thermometer 30 minutes after application.10 Despite this promising information, not enough data yet exists to suggest that arginine transdermal is appropriate for the management of ED. Though there is limited information to support transdermal application of medication for ED, some data exists to suggest efficacy. The transdermal route could be considered for patients who prefer not to use oral or injectable medications. Check out the Fagron Academy site for related formulas. S.

  • Ed gels should be applied with a clean finger or applicator for hygiene.
  • They may cause temporary numbness or a tingling sensation in the mouth.
  • Excessive use can lead to systemic absorption and potential side effects.
  • Patients should avoid eating or drinking immediately after application.

Food and Drug Administration (FDA) to treat ED. Topical ED treatments are still in development. You may have heard of the topical testosterone drug called AndroGel. However, AndroGel is not approved by the U.S. Food and Drug Administration (FDA) to treat ED specifically, and it’s not meant to be used on the genitals.

Limitations of topical gels

It is 3mg/g alprostadil and is packaged in single dose syringes carrying 100mg of cream, equivalent to 300mcg alprostadil. Phase II and III trials demonstrated up to 83% efficacy with this product with only 3% of the treated population reporting systemic adverse effects.3 In addition to intraurethral administration, some studies have also evaluated topical/transdermal use. One study of alprostadil 1% had patients apply 0.25ml of alprostadil 1% or placebo gel to the glans penis. The study reported better responses to the alprostadil treatment at all timepoints, with greatest differences noted at 45 and 60 minutes after application. The study noted that of the tested patients 38.9% in the treatment group and 6.9% in the placebo group achieved an erection deemed sufficient for penetration.4 Some studies have also evaluated tadalista tablets papaverine HCl for transdermal use.

NEW Eroxon® may be the recommendation your patients need

One study of drug release of papaverine HCl in a gel vehicle found an alcohol-containing penetration enhancer resulted in drug penetration both in vitro and in vivo in rabbits. The study suggested that their results supported the use of penetration enhancer to deliver papaverine HCl transdermally.5 Another study evaluated 15% and 20% papaverine HCl gel applied to the scrotum, perineum, and penis. Patient response was evaluated 45 minutes after treatment. The treatment was well tolerated and papaverine HCl was minimally systemically absorbed, the researchers hypothesized that effects seen, mainly increase in duration of erection compared to placebo, were a result of local rather than systemic absorption.6 Phentolamine mesylate, while sometimes included in transdermal erectile dysfunction combination products, has not currently been studied in well controlled trials for its potentially efficacy via the transdermal route. Sildenafil is a PDE5 Inhibitor commercially available for oral use for ED, but there is some information to suggest that it may be efficacious transdermally as well. Rather, Androgel is approved to help increase levels of testosterone in some men who have abnormally low testosterone levels. It’s possible for erectile function to improve in men who take it who have ED related to abnormally low testosterone levels.

Gel Type Typical pH Range Suitable Fruits/Fluids Comments
Gelatin 5.0 - 9.0 Fruit juices, broth Sensitive to acidity
Agar-Agar 3.0 - 10.0 Fruit juices, water Stable across pH levels
Pectin 2.0 - 4.0 Citrus, apple juices Needs acid for gelation
Carrageenan 6.0 - 8.0 Milk, water Works over a broad pH range

But this gel wouldn’t help men whose ED is caused by factors other than low testosterone levels.

Gel Type Gelation Temperature Melting Temperature Storage Stability
Gelatin 10°C - 15°C 20°C - 25°C Moderate
Agar-Agar 32°C - 40°C >85°C High
Carrageenan 35°C - 40°C >70°C Moderate
Pectin 4°C - 10°C ~20°C Good when stored cold

For more information about the proper use of topical testosterone drugs, read about Axiron and Androgel for low testosterone.

  • Ed gels are topical anesthetics used during dental procedures to numb tissues.
  • They typically contain lidocaine, benzocaine, or prilocaine as active ingredients.
  • Ed gels provide quick numbing effects, usually within a few minutes of application.
  • They are applied directly to the gums or oral mucosa for pain relief.

Vasodilators help relax blood vessels to improve blood flow.

Use caution with unproven ED treatments

The product includes 4 single-use tubes and retails for $25.99. Haleon announces the launch of Eroxon®, the first and only FDA cleared OTC gel for erectile dysfunction, available for US preorder without a prescription. Erectile dysfunction (ED) is a common patient concern, and its prevalence is strongly associated with age. Data from the US National Heath and Nutrition Examination Survey suggests that 8.2% of men between ages 40-49 years and 77.5% of men greater than 75 years old suffer from erectile dysfunction.1 The prevalence of ED was also associated with other conditions such as diabetes mellitus, smoking, cardiovascular disease, hypertension, and obesity.1 ED is most commonly managed with prescription phosphodiesterase-5 (PDE5) inhibitors used orally such as sildenafil, tadalafil, or vardenafil.1 Commercially available injectables for ED such as alprostadil or phentolamine mesylate injections are also sometimes used. Compounded options for ED often include combination injectable products such as phentolamine mesylate/papaverine HCl/alprostadil combinations, commonly referred to as “Tri-mix”.

Quick Choice Guide (What to pick)

Tri-mix injections can be associated with serious side effects. One study evaluating trimix use and reasons for dropout in 189 patients noted that 30% of patients discontinued Tri-mix due to lack of efficacy, 5.2% experienced fibrosis or scarring, and 3.7% reported priapism.2 While Tri-mix works well for many patients, adverse effects make this route inappropriate for some patients creating a need for alternatives. In this newsletter, we will discuss existing evidence for the use of topically administered treatments, for the management of ED. Alprostadil is available in the United States as an injectable for ED as well as an intraurethral suppository, but in other countries, there are alternatives such as intraurethral alprostadil. Vitaros is an intraurethral cream available in some European countries as well as Canada. Alprostadil is a vasodilator that treats ED effectively for many men.

Additive Purpose Effect on Gel Properties Regulatory Status
Stabilizers Enhance stability Increased shelf life Approved in small amounts
Sweeteners Improve taste May alter gelling behavior Varies by region
Emulsifiers Improve texture Smoother, more elastic Approved in food
Preservatives Extend shelf life Prevent microbial growth Allowed in regulated amounts

To treat ED in the United States, alprostadil is currently only available in an injectable form or urethral suppository, which is a pellet that you insert into the opening of your penis.

Common uses of Gels

Papaverine topical gel for treatment of erectile dysfunction. Yonessi M, Saeedi M. A double-blind placebo-controlled evaluation of the effect of topical sildenafil on erectile dysfunction. Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: a randomized double-blind, controlled pilot study. Possible benefit of tadalafil cream for the treatment of Raynaud’s phenomenon and digital ulcers in systemic sclerosis.

Scroll to top

Dr. med. Fabienne Gretener

Werdegang

Januar 2024 bis heute
Oberärztin SenoMed AG
Schwerpunktsweiterbildung gynäkologische Senology

März 2023 – Dezember 2023
Oberärztin, SenoMed AG Bern 20%

Januar 2023 – November 2023
Assistenzärztin Psychiatrie, Klinik Meissenberg Zug

Januar 2021 – November 2022
Assistenzärztin Gynecology und Geburtshilfe, Bürgerspital Solothurn

November 2019 – Oktober 2020
Assistenzärztin Gynecology und Geburtshilfe, Kantonsspital Aarau

Januar 2017 – Juli 2019
Assistenzärztin Gynecology und Geburtshilfe, Kantonsspital Olten

Paul Laszlo Bernhard

Werdegang

Jan 2024 bis heute
Facharzt SenoMed AG – Brustzentrum Bern Biel

Aug 2019 – Dez 2023
Oberarzt Frauenklinik und Brustzentrum Bürgerspital, Solothurn, Schwerpunktweiterbildung operative Gynecology und Geburtshilfe sowie Senology

Mai 2019 Facharzttitel Gynecology & Geburtshilfe

Apr 2016 – Jul 2019
Arzt in Weiterbildung, Inselspital Bern, Universitätsklinik für Frauenheilkunde

Dez 2014 – Apr 2016
Arzt in Weiterbildung, Kantonsspital Baden

Sep 2012 – Sep 2014
Arzt in Weiterbildung, Universitätsklinikum Carl Gustav Carus, Dresden

Feb 2012 – Sep 2012
Arzt in Weiterbildung, Universitätsfrauenklinik Leipzig

Nov 2011 Approbation zum Arzt

2005 – 2011
Studium der Humanmedizin an der Charité, Universitätsmedizin Berlin

Dr. med. Patrizia Sager

Werdegang

Okt 2023 bis heute
Leiterin Weiterbildungsstätte gynäkologische Senology

Feb 2018 – bis heute
Leiterin Brustzentrum Bern Biel
Practiceinhaberin SenoMed AG

Nov 2017 – bis heute
Belegärztin Salem-Spital Bern

Jan 2013 – Okt 2017
Leitung Senology Brustzentrum Frauenklinik Universitätsspital Insel, Bern

Jan 2012 – Dez 2012
Oberärztin Gynecology / Geburtshilfe, Frauenklinik Universitätsspital Insel, Bern

Nov 2010 – Dez 2011
Leitende Ärztin Gynecology und Geburtshilfe, Frauenklinik Rheinfelden (DE)

Nov 2009 – Okt 2010
Oberärztin Gynecology und Geburtshilfe, Kantonsspital Liestal

Jan 2009 – Okt 2009
Oberärztin i.V. Gynecology und Geburtshilfe, Regionalspital Interlaken

Jun 2008 – Dez 2008
Assistenzärztin Gynecology und Geburtshilfe, Regionalspital Interlaken

Aug 2007 – Mai 2008
Assistenzärztin Gynecology und Geburtshilfe, Universitätsspital Zürich

Feb 2007 – Jun 2007
Oberärztin Gynecology und Geburtshilfe, Universitätsspital Groote Schuur, Kapstadt, Südafrika

Jan 2004 – Dez 2006
Assistenzärztin Gynecology und Geburtshilfe, Regionalspital Thun

Jan 2003 – Dez 2003
Assistenzärztin Chirurgie und Orthopädie, Regionalspital Thun

Schulen, Studium & Diplome

2023
Schwerpunkt gynäkologische Senology

2014
Diplom Senology SGGG

2013
Diplom Senology: European Academy of Senology

2010
FMH Gynecology und Geburtshilfe inkl. Schwerpunkt operative Gynecology

2003
Promotion

2002
Staatsexamen in Humanmedizin

1996 – 2002
Humanmedizinstudium Universitätsspital Basel

Mitglied- und Partnerschaften

  • Schweizerische Gesellschaft für Gynecology und Geburtshilfe SGGG
  • Schweizerische Gesellschaft für Senology SGS
  • Mitglieder Arbeitsgemeinschaft Gynäkologische Onkologie AGO, Schweiz
  • European Academy of Senology EAoS
  • SAKK Project-Group breast cancer
  • Schweizerische Gesellschaft für Ultraschall in der Medizin SGUM
  • Verbindung der Schweizer Ärzte und Ärztinnen FMH
  • Society of women in senology SWIS
  • Vorstandsmitglied Ärztenetzwerk Bern